PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli（PEG-rhG-CSF） in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: nab-paclitaxel, 260mg/m2, intravenous infusion for 30 minutes, D1, Q3W. S-1, 80-120mg, PO BID, D1-14, Q3W. (2) patients who met the eligibility criteria were given jinyouli injections 24 hours after the end of intravenous infusion of nab-paclitaxel during the treatment period.
PEG-rhG-CSF|Pancreatic Cancer
DRUG: Jin Youli(PEG-rhG-CSF)
Incidence of degree 3-4 neutropenia in each cycle of chemotherapy, Incidence of degree 3-4 neutropenia in each cycle of chemotherapy, last 4 cycles(each cycle is 21 days)
The incidence of febrile neutropenia in each cycle of chemotherapy, Febrile neutropenia (FN) is defined as oral temperature \>38.3℃ or continuous measurement of oral temperature \>38.1℃ in 1h, with ANC \<0.5×10\^9/L or expected to be \<0.5×10\^9/L, last 4 cycles(each cycle is 21 days)|Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy, Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy, last 4 cycles(each cycle is 21 days)|The proportion of patients hospitalized due to neutropenia, The proportion of patients hospitalized due to neutropenia, last 4 cycles(each cycle is 21 days)|The proportion of patients receiving antibiotics during the entire chemotherapy period., The proportion of patients receiving antibiotics during the entire chemotherapy period., last 4 cycles(each cycle is 21 days)
A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli（PEG-rhG-CSF） in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: nab-paclitaxel, 260mg/m2, intravenous infusion for 30 minutes, D1, Q3W. S-1, 80-120mg, PO BID, D1-14, Q3W. (2) patients who met the eligibility criteria were given jinyouli injections 24 hours after the end of intravenous infusion of nab-paclitaxel during the treatment period.